Professional Documents
Culture Documents
2. PRN Number *
Captopril
Hydrochorothiazide
Lidocaine
Quinidine
Sulfasalazine
https://docs.google.com/forms/d/1wqFjbVUU-9mqhvdJpQjKiEDNLmyK49QDhQLbDwKdAf0/edit 1/8
7/6/2021 Pharmacology-II (PR) (Subject Code : BP507P) Batch - E
5. A treatment of angina that consistently decreases the heart rate and can prevent
vasospastic angina attacks is .... *
Isosorbide dinitrate
NIFedipine
Nitroglycerin
Propranolol
Verapamil
6. In a patient receiving digoxin for congestive heart failure, condition that may
facilitate the appearance of toxicity include .... *
Hyperkalemia
Hypernatremia
Hypocalcemia
Hypomagnesemia
Intrinsic pathway
Extrinsic pathway
Common pathway
No any pathway
https://docs.google.com/forms/d/1wqFjbVUU-9mqhvdJpQjKiEDNLmyK49QDhQLbDwKdAf0/edit 2/8
7/6/2021 Pharmacology-II (PR) (Subject Code : BP507P) Batch - E
Bleeding time
Prothrombin time
Blood pressure
9. Which of the following can be used to antagonize the action of heparin in case of
overdose ? *
Heparin sulfate
Dextran sulfate
Protamine sulfate
Ancrod
10. Blood level of which clotting factor declines most rapidly after the initiation of
warfarin therapy *
Factor VII
Factor IX
Factor X
Prothrombin
https://docs.google.com/forms/d/1wqFjbVUU-9mqhvdJpQjKiEDNLmyK49QDhQLbDwKdAf0/edit 3/8
7/6/2021 Pharmacology-II (PR) (Subject Code : BP507P) Batch - E
Cimetidine
Aspirin
Oral contraceptive
12. The most definite beneficial results are obtained in the use of anticoagulants for
the following purpose *
Cerebrovascular accident
Buerger’s disease
All of these
https://docs.google.com/forms/d/1wqFjbVUU-9mqhvdJpQjKiEDNLmyK49QDhQLbDwKdAf0/edit 4/8
7/6/2021 Pharmacology-II (PR) (Subject Code : BP507P) Batch - E
Hypotension
Bleeding
Fever
Anaphylaxis
Intravenous
Subcutaneous
Intracoronary
Intracardiac
Thromboxane A2 in platelets
https://docs.google.com/forms/d/1wqFjbVUU-9mqhvdJpQjKiEDNLmyK49QDhQLbDwKdAf0/edit 5/8
7/6/2021 Pharmacology-II (PR) (Subject Code : BP507P) Batch - E
Oral
Subcutaneous
Intramuscular
Sublingua
18. Severe cases of bleeding due to fibrinolytic agents are treated with *
Aspirin
Heparin
Vitamin K
Plasma expander
Haemostatic
Heparin substitute
https://docs.google.com/forms/d/1wqFjbVUU-9mqhvdJpQjKiEDNLmyK49QDhQLbDwKdAf0/edit 6/8
7/6/2021 Pharmacology-II (PR) (Subject Code : BP507P) Batch - E
Aqueous diffusion
Aqueous hydrolysis
Lipid diffusion
Pinocytosis or endocytosis
Depends on the unbound drug concentration gradient between blood and tissue
Weak acids
Strong acids
Weak Bases
https://docs.google.com/forms/d/1wqFjbVUU-9mqhvdJpQjKiEDNLmyK49QDhQLbDwKdAf0/edit 7/8
7/6/2021 Pharmacology-II (PR) (Subject Code : BP507P) Batch - E
Parasympathetic ganglia
Skeletal muscle
Sympathetic ganglia
Forms
https://docs.google.com/forms/d/1wqFjbVUU-9mqhvdJpQjKiEDNLmyK49QDhQLbDwKdAf0/edit 8/8